First Amyloid Antibody Infusion at the Memory Clinic in Magdeburg
DZNE will scientifically accompany treatment with “Lecanemab”
Magdeburg, September 11, 2025. In scientific cooperation with DZNE, the Memory Clinic at Magdeburg University Hospital’s Department of Neurology recently became one of the first institutions in Germany to administer an amyloid antibody infusion with the newly approved drug Lecanemab (Leqembi). This drug provides the first therapy to address causes of Alzheimer’s disease.
“Though this drug cannot stop the progression of the disease, it can slow it down. This is a milestone in the treatment of people with mild cognitive impairment or mild dementia due to Alzheimer’s disease,” said Dr. Wenzel Glanz, senior physician at the Memory Clinic and DZNE scientist. “With a newly created infusion infrastructure at the Memory Clinic in Magdeburg with four infusion units, we are now able to offer this new therapy to our patients.”
DZNE will monitoring the use of the drug in a scientific study – not only in Magdeburg, but also at other sites across Germany. This endeavor builds on the research network established by DZNE, which involves cooperation with university hospitals. The findings are to contribute to the further development of the treatment and help to prevent side effects.
Proven collaboration
The Magdeburg Memory Clinic is based on a collaboration between the University Hospital’s Department of Neurology and DZNE. Thus, close ties between clinical care and scientific support in the field of dementia, have been maintained for many years.